StockData
AtriCure, Inc. logo

AtriCure, Inc. (ATRC) company profile

ATRCNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 12/30893% above fair value
$55.02−0.29 (-0.52%)

Close on Nov 17, 2026Market cap $2.80BP/E 262.0Yield –

About AtriCure

Surgical & Medical Instruments & Apparatus, SIC 3841

AtriCure develops and markets surgical devices and therapies designed to treat atrial fibrillation, manage the left atrial appendage, and control post-operative pain. Its primary solutions include cardiac ablation platforms utilizing radiofrequency and cryogenic energy, left atrial appendage exclusion systems under the AtriClip brand, and cryoablation probes for cryo nerve block. The company offers these technologies to medical centers and specialized clinicians, including cardiac and thoracic surgeons as well as electrophysiologists, for use in open-heart, minimally invasive, and amputation procedures.

The business commercializes its product portfolio through a direct sales organization across the United States, Germany, France, the United Kingdom, the Benelux region, Australia, and Canada. Additionally, third-party distributors market and distribute these surgical devices to medical facilities in other international territories. The provided report does not state the company's corporate headquarters, facility counts, or founding date.

Summary of the business section of AtriCure's latest annual report, written by StockData.

Company profile

Company

Legal name
AtriCure, Inc.
Founded
2000
Headquarters
Mason, OH
Address
7555 Innovation Way 45040
Phone
(513) 755-4100
Employees
1,350, Dec 31, 2025
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Deloitte & Touche LLP, Cincinnati, Ohio

Stock & identifiers

Ticker
ATRC
Exchange
Nasdaq
IPO date
Aug 8, 2005
Shares outstanding
51M, Jul 22, 2026
Public float
$1.57B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1323885
CUSIP
04963C209
ISIN
US04963C2098
FIGI
BBG000BL6CB5
Share class FIGI
BBG001SD43V3
LEI
254900B2I6GPHK2EXM59
EIN
34-1940305

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Michael H. CarrelPresident, CEO, & Director796,694
Salvatore PriviteraChief Technical Officer134,341
Karl S. DahlquistChief Legal Officer87,319
Justin J. NozneskyChief Mktg & Strategy Officer100,219
Vinayak DoraiswamyChief Scientific Officer86,511
Douglas J. SeithChief Operating Officer229,867
Angela L. WirickChief Financial Officer204,893
Deborah Lee YountChief Human Resources Officer57,539
B. Kristine JohnsonDirector53,502
Regina E. GrovesDirector34,546
Maggie YuenDirector14,015
Karen PrangeDirector22,809
Sven WehrweinDirector40,518
Deborah H. TelmanDirector28,328
Robert S. WhiteDirector128,318
Shlomo NachmanDirector24,655

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$9.22M$14.94M$3.17M$71$81
FY2024$11.07M$6.77M$3.04M$55$66
FY2023$8.75M$4.76M$2.67M$64$68
FY2022$8.35M$248.18K$2.26M$80$68
FY2021$7.54M$13.12M$2.14M$125$90
FY2020$5.57M$13.75M$1.44M$171$127

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsIncentive payOtherTotalvs. prior year
Michael H. Carrel
President and Chief Executive Officer
$828.44K$7.20M$1.17M$14.00K$9.22M-17%
Angela L. Wirick
Chief Financial Officer
$523.37K$2.54M$504.45K$11.75K$3.57M+9%
Douglas J. Seith
Chief Operating Officer
$572.22K$2.70M$659.39K$21.20K$3.95M-4%
Salvatore Privitera
Chief Technical Officer
$447.77K$1.89M$364.22K$14.00K$2.71M–
Justin J. Noznesky
Chief Marketing and Strategy Officer
$452.11K$1.62M$367.75K$11.75K$2.45M+8%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Aug 8, 2005
Offer price
$12.00
Securities offered
4,000,000
Gross proceeds
$48.00M
Exchange
Nasdaq
First trading day
Aug 5, 2005
First-day close
$14.08+17.3%
Lock-up ends (est.)
Feb 1, 2006

“Per share Total Public offering price $ 12.00 $ 48,000,000 Underwriting discounts and commissions $ 0.84 $ 3,360,000 Proceeds, before expenses, to us $ 11.16 $ 44,640,000 We and certain of our shareholders have granted the underwriters an option to purchase up to an additional 600,000 shares of our common stock at”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had approximately 1,350 employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?